Examples of KRAS-on inhibitors include RM-018, a KRASG12C covalent inhibitor that interacts with cyclophilin A and targets KRASG12C in its GTP-bound state.193 In a published clinical case report, a patient with KRASG12C NSCLC who developed resistance to adagrasib was treated with RM-018, which could overcome resistance.193 Resistance in this case was mediated via the recycling of KRAS into its GTP-active form, leading to reactivation of the RAS-MAPK signaling pathway. Here, KRAS is linked to non-small cell lung carcinoma.